LAVA Therapeutics NV Profit Margin

As of the most recent data (September 2025), LVTX shows a profit margin of -466.43%. That compares with -365.02% in the prior-year period — down 27.8% year over year. That is below the Healthcare sector average of 14.41%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LVTX's profit margin is now -466.43% (was -365.02%) — a 27.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether LAVA Therapeutics NV is outperforming or lagging.

The Healthcare sector average profit margin is about 14.41%. LAVA Therapeutics NV is at -466.43%, which is lower that average. That is roughly 3335.8% below the sector mean. Use the comparison chart on this page to see how LVTX stacks up against individual peers as well.

That compares with -365.02% in the prior-year period — down 27.8% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare LAVA Therapeutics NV with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has LAVA Therapeutics NV's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -466.43%) with ownership activity and broader fundamentals.